PRKAA1 and neoplasm: This same group later identified that clinically achievable doses of metformin (low μM range) were able to enhance radiation responses in vivo by blocking tumor angiogenesis and Akt-mTOR signaling, as well as enhancing apoptosis through the ATM-AMPK pathway [121].